Bicara Therapeutics BCAX Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares

Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares at other companies

WSFS FinancialWSFS

0-100%

Flagstar Bank FLG

5.7M-39.3%

WaFd, Inc.WAFD

827.8K-1.8%

MSCIMSCI

577K+63.9%

SBA CommunicationsSBAC

14K-30.0%

Tarsus Pharmaceuticals, Inc.TARS

1.5M-13.8%

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Market cap$1.68B+81.4%

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Bicara Therapeutics's sharebased compensation arrangement by sharebased payment award options nonvested number of shares?: Bicara Therapeutics (BCAX) reported sharebased compensation arrangement by sharebased payment award options nonvested number of shares of 8.5M in Q1 2026.
How has Bicara Therapeutics's sharebased compensation arrangement by sharebased payment award options nonvested number of shares changed year-over-year?: Bicara Therapeutics's sharebased compensation arrangement by sharebased payment award options nonvested number of shares increased by 31.5% year-over-year, from 6.5M to 8.5M.